James E. Wagner Cultivation Corporation Announces Health Canada Approval for Additional Production Capacity at JWC 2
James E. Wagner Cultivation Corporation (“JWC” or the “Corporation”) (TSXV:JWCA, OTCQX:JWCAF), is pleased to announce that on June 28, 2019, it received approval of a licence amendment from Health Canada, permitting it to grow cannabis in additional flowering rooms at the Corporation’s flagship facility, JWC 2, located at 530 Manitou Drive in Kitchener, Ontario. The newly approved flowering rooms will add approximately 11,000 sq. ft., resulting in a total of nearly 22,000 sq. ft. of flowering space at JWC 2.
Reacting to the Corporation’s latest approval from Health Canada, President & Chief Executive Officer, Nathan Woodworth commented, “The approval of this new space represents a significant step in the continuing journey toward full scale production at JWC 2. Our team is excited to begin cultivation in our new spaces; we are already preparing plants to move into these new rooms. The crops harvested from our Phase 2 rooms will allow us to supply a much wider market than was previously possible.”
The additional flowering rooms approved by Health Canada are the result of the previously press released Phase 2 construction of JWC 2. At full-scale, JWC 2 will measure 345,000 sq. ft. and is expected to be fully equipped with the Corporation’s GrowthSTORM™ Dual Droplet™ System. The proprietary GrowthSTORM™ Dual Droplet™ System is a cultivation system that uses two separate nutrient solutions, delivered to the plant’s root system through two distinct channels, all housed within a single enclosure.
The JWC team has already completed a variety of preparations designed to populate the new Phase 2 flowering rooms with plants shortly after receiving this Health Canada approval. Unlike the Corporation’s existing flowering room floor plan employed in the Pre-Phase 2 space (the “Phase 1 Space”), which consists of 8 flowering rooms, the new Phase 2 area features 2 flowering rooms in total, each of which is roughly 4 times larger in size than each of the existing flowering rooms. While the total size of the new Phase 2 area is comparable to the Phase 1 Space, JWC expects this modified division of space has the potential to maximize yields without sacrificing operational integrity, as well as increase the total amount of usable floor space.
JWC – Clean. Consistent. Aeroponic.
About James E. Wagner Cultivation Corporation
JWC’s wholly-owned subsidiary is a Licensed Producer under the Cannabis Regulations, formerly the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). JWC is a premium cannabis brand, focusing on producing clean, consistent cannabis. JWC uses an advanced and proprietary Dual Droplet™ aeroponic platform named GrowthSTORM™. JWC was founded as a family company and is based on family values. JWC began as a collective of patients and growers under the Marihuana Medical Access Regulations (the precursor to ACMPR). Since its inception, JWC has remained focused on providing the best possible patient experience. JWC’s operations are based in Kitchener, Ontario. Learn more at www.jwc.ca.
Notice regarding forward-looking statements:
This press release contains statements including forward-looking information for purposes of applicable securities laws (“forward-looking statements”) about JWC and its business and operations which include, among other things, statements regarding the use and anticipated yields of product from the additional cultivation space, the benefits of the future deployment of larger flowering rooms, the anticipated equipment to be used in Phase 2, timing for population of the Phase 2 space and the anticipated ability to supply a much wider market on the basis of the crops from the Phase 2 rooms. The forward-looking statements can be identified by the use of such words as “will”, “expected”, “approximately”, “may”, “could”, “would” or similar words and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to differ materially from those implied in the forward-looking statements. For example, risks include risks regarding the cannabis industry, economic factors, the equity markets generally, building permit related risks, technology-related risks, risks related to crop production, useable area and risks associated with growth and competition as well as the risks identified in the Corporation’s Annual Information Form dated April 3, 2019 available under the Corporation’s profile at www.sedar.com. Although JWC has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and are based on current assumptions which management believes to be reasonable. The Corporation disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.